CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
B244 +1 moredrug
Likely dose
B244 spray: 10 pumps (1.4 mL) applied twice daily to entire face for 14 daysAI-extracted
Key inclusion· 4
  • Age 18–45 years
  • Good general health with normal ECG, vital signs, and clinical laboratory results
  • Facial acne vulgaris: ≥105 inflammatory lesions, ≥10 non-inflammatory lesions, IGA ≥2
  • Willing to refrain from other acne treatments on face (except non-systemic agents on back/shoulders/chest)
Key exclusion· 10
  • Pregnancy, lactation, or attempting to conceive; positive β-hCG at screening or pre-dose
  • Skin conditions interfering with safety/efficacy assessment (rosacea, seborrheic dermatitis, perioral dermatitis, corticosteroid-induced acne/folliculitis)
  • Active cystic acne, acne congoblata, acne fulminans, or secondary acne
  • Two or more active nodular lesions

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02656485
NCT02656485Phase 2Completed

A Double Blind, Placebo-Controlled, Single Center, Randomized, Sequential, Ascending 14-Day Multiple Dose Study in Subjects With Acne Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 Delivered as a Topical Spray

AOBiome LLC·interventional·Posted Jan 15, 2016·Updated Apr 5, 2017

In Brief

A Phase 2 clinical trial evaluating B244 and Placebo for Acne Vulgaris. Completed, enrolled 36 participants across 1 site.

Detailed Summary

This is a single center, randomized, double-blind, placebo-controlled study in subjects with acne vulgaris.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 15, 2016
Enrollment StartAug 5, 2015
Primary CompletionMar 1, 2016
Study CompletionJul 15, 2016
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 10.5 years ago

Interventions

B244drug

10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days

Placebodrug

10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days